Sara Canovas Nunes, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Janus Kinases | 1 | 2018 | 244 | 0.570 |
Why?
|
| ras Proteins | 1 | 2022 | 1060 | 0.570 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 873 | 0.570 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2018 | 293 | 0.550 |
Why?
|
| Casein Kinase II | 3 | 2023 | 128 | 0.390 |
Why?
|
| Cell Cycle | 2 | 2018 | 2967 | 0.360 |
Why?
|
| Signal Transduction | 5 | 2023 | 23403 | 0.340 |
Why?
|
| Cell Movement | 1 | 2018 | 5217 | 0.260 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3703 | 0.260 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 5181 | 0.220 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 6 | 1 | 2022 | 29 | 0.210 |
Why?
|
| Receptors, Antigen, B-Cell | 2 | 2023 | 548 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 2503 | 0.150 |
Why?
|
| Naphthyridines | 1 | 2018 | 118 | 0.150 |
Why?
|
| Casein Kinase I | 1 | 2017 | 47 | 0.150 |
Why?
|
| Oxazines | 1 | 2018 | 298 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2018 | 1792 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2023 | 5524 | 0.100 |
Why?
|
| beta Catenin | 1 | 2017 | 1059 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1376 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1378 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2016 | 2499 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2018 | 1972 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 16689 | 0.070 |
Why?
|
| Pyridines | 1 | 2018 | 2825 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 2942 | 0.070 |
Why?
|
| Apoptosis | 1 | 2018 | 9727 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 3523 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 1437 | 0.040 |
Why?
|
| Phenazines | 1 | 2018 | 58 | 0.040 |
Why?
|
| Cell Survival | 2 | 2017 | 5882 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 365 | 0.030 |
Why?
|
| Morpholines | 1 | 2018 | 571 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 380 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2018 | 542 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 936 | 0.030 |
Why?
|
| Thalidomide | 1 | 2017 | 890 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1880 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2018 | 10481 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 2025 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 6314 | 0.020 |
Why?
|
| Humans | 5 | 2022 | 744343 | 0.020 |
Why?
|
| Piperidines | 1 | 2018 | 1602 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4751 | 0.020 |
Why?
|
| RNA Interference | 1 | 2017 | 2889 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2023 | 14557 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2948 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2023 | 11483 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13695 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7799 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15997 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 57776 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 5172 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2017 | 19229 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8428 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5535 | 0.010 |
Why?
|
| Mice | 1 | 2023 | 81183 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 163280 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 213383 | 0.010 |
Why?
|
| Adult | 2 | 2017 | 214055 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 168757 | 0.010 |
Why?
|
| Male | 2 | 2017 | 350118 | 0.010 |
Why?
|
| Female | 2 | 2017 | 380194 | 0.000 |
Why?
|